In a recent study published in the journal Lancet Oncology, researchers compared everolimus versus sunitinib in 108 patients with metastatic papillary, chromophobe, or unclassified non–clear-cell renal cell carcinoma (RCC) in a phase 2 randomised, industry-sponsored clinical trial. Nearly two thirds of the patients had papillary histology. Progression-free survival was longer with sunitinib in patients with papillary and unclassified histologies, but longer with everolimus in those with chromophobe histology. Overall survival was similar in both treatment arms and the side effect profile was consistent with that expected for sunitinib and everolimus.
Sunitinib vs everolimus for advanced non-clear cell kidney cancer
9 May 2016
Afinitor
chromophobe RCC
everolimus
non-clear cell kidney cancer
papillary RCC
subtype of RCC
sunitinib
Sutent
Most used tags
renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib Sutent progression-free survival cabozantinib biomarkers NHS England Cabometyx ipilimumab COVID-19 pembrolizumab cancer survival axitinib VEGF inhibitors non-clear cell kidney cancer Inlyta coronavirus Yervoy risk factors Keytruda metastases adjuvant therapy biological markers targeted therapy papillary RCC everolimus Afinitor ASCO cancer outcomes first-line treatment NICE partial nephrectomyArchives
- 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
- 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec